"Complement C4" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A glycoprotein that is important in the activation of CLASSICAL COMPLEMENT PATHWAY. C4 is cleaved by the activated COMPLEMENT C1S into COMPLEMENT C4A and COMPLEMENT C4B.
- Complement C4
- C4, Complement
- Complement Component 4
- Component 4, Complement
- Complement 4
- C4 Complement
- Complement, C4
- C4 Complement Component
- Complement Component, C4
- Component, C4 Complement
Below are MeSH descriptors whose meaning is more general than "Complement C4".
Below are MeSH descriptors whose meaning is more specific than "Complement C4".
This graph shows the total number of publications written about "Complement C4" by people in this website by year, and whether "Complement C4" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
|Year||Major Topic||Minor Topic||Total|
To return to the timeline, click here.
Below are the most recent publications written about "Complement C4" by people in Profiles.
Low copy numbers of complement C4 and C4A deficiency are risk factors for myositis, its subgroups and autoantibodies. Ann Rheum Dis. 2023 Feb; 82(2):235-245.
Cell-bound complement activation products associate with lupus severity in SLE. Lupus Sci Med. 2020 04; 7(1).
Complement Activation in Patients With Probable Systemic Lupus Erythematosus and Ability to Predict Progression to American College of Rheumatology-Classified Systemic Lupus Erythematosus. Arthritis Rheumatol. 2020 01; 72(1):78-88.
How immunological profile drives clinical phenotype of primary Sjögren's syndrome at diagnosis: analysis of 10,500 patients (Sjögren Big Data Project). Clin Exp Rheumatol. 2018 May-Jun; 36 Suppl 112(3):102-112.
Kidney Outcomes and Risk Factors for Nephritis (Flare/De Novo) in a Multiethnic Cohort of Pregnant Patients with Lupus. Clin J Am Soc Nephrol. 2017 Jun 07; 12(6):940-946.
Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2016 Feb; 75(2):332-40.
TAM receptor ligands in lupus: protein S but not Gas6 levels reflect disease activity in systemic lupus erythematosus. Arthritis Res Ther. 2010; 12(4):R146.
The partly folded back solution structure arrangement of the 30 SCR domains in human complement receptor type 1 (CR1) permits access to its C3b and C4b ligands. J Mol Biol. 2008 Jan 04; 375(1):102-18.
Immune complex size and complement regulate cytokine production by peripheral blood mononuclear cells. Clin Immunol. 1999 Dec; 93(3):274-82.
Activation of complement by human IgG1 and human IgG3 antibodies against the human leucocyte antigen CD52. Immunology. 1998 Apr; 93(4):595-600.